

Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/H681AA67BEF3EN.html>

Date: March 2022

Pages: 62

Price: US\$ 3,250.00 (Single User License)

ID: H681AA67BEF3EN

Abstracts

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

This report contains market size and forecasts of Human Immunodeficiency Virus (HIV)-1 Therapeutics in Global, including the following market information:

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market was valued at 12220 million in 2021 and is projected to reach US\$ 12890 million by 2028, at a CAGR of 0.8% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Human Immunodeficiency Virus (HIV)-1 Therapeutics include AbbVie, Inc.(U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Boehringer Ingelheim GmbH (Germany), Genentech, Inc. (U.S.) and Cipla, Inc.

(India), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Immunodeficiency Virus (HIV)-1 Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, by Type, 2021 (%)

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Entry and Fusion Inhibitors

Protease Inhibitors (PIs)

Integrase Inhibitors

Coreceptor Antagonists

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Labs

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Human Immunodeficiency Virus (HIV)-1 Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Human Immunodeficiency Virus (HIV)-1 Therapeutics revenues share

in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AbbVie, Inc.(U.S.)

Merck & Co., Inc. (U.S.)

Bristol-Myers Squibb Company (U.S.)

Boehringer Ingelheim GmbH (Germany)

Genentech, Inc. (U.S.)

Cipla, Inc. (India)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV)-1 THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players in Global Market
- 3.2 Top Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies Ranked by Revenue
- 3.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Type

3.6 Tier 1, Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players in Global Market

3.6.1 List of Global Tier 1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

4.1.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

4.1.4 Entry and Fusion Inhibitors

4.1.5 Protease Inhibitors (PIs)

4.1.6 Integrase Inhibitors

4.1.7 Coreceptor Antagonists

4.2 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Labs

5.2 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2028

6.3.2 US Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.3.3 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.3.4 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2028

6.4.2 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4.3 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4.4 U.K. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4.5 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4.6 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.4.8 Benelux Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2028

6.5.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.5.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.5.4 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.5.6 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2028

6.6.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.6.3 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2028

6.7.2 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.7.3 Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

6.7.5 UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AbbVie, Inc.(U.S.)

- 7.1.1 AbbVie, Inc.(U.S.) Corporate Summary
- 7.1.2 AbbVie, Inc.(U.S.) Business Overview
- 7.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
- 7.1.4 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2017-2022)
- 7.1.5 AbbVie, Inc.(U.S.) Key News
- 7.2 Merck & Co., Inc. (U.S.)
 - 7.2.1 Merck & Co., Inc. (U.S.) Corporate Summary
 - 7.2.2 Merck & Co., Inc. (U.S.) Business Overview
 - 7.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
 - 7.2.4 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2017-2022)
 - 7.2.5 Merck & Co., Inc. (U.S.) Key News
- 7.3 Bristol-Myers Squibb Company (U.S.)
 - 7.3.1 Bristol-Myers Squibb Company (U.S.) Corporate Summary
 - 7.3.2 Bristol-Myers Squibb Company (U.S.) Business Overview
 - 7.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
 - 7.3.4 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2017-2022)
 - 7.3.5 Bristol-Myers Squibb Company (U.S.) Key News
- 7.4 Boehringer Ingelheim GmbH (Germany)
 - 7.4.1 Boehringer Ingelheim GmbH (Germany) Corporate Summary
 - 7.4.2 Boehringer Ingelheim GmbH (Germany) Business Overview
 - 7.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
 - 7.4.4 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2017-2022)
 - 7.4.5 Boehringer Ingelheim GmbH (Germany) Key News
- 7.5 Genentech, Inc. (U.S.)
 - 7.5.1 Genentech, Inc. (U.S.) Corporate Summary
 - 7.5.2 Genentech, Inc. (U.S.) Business Overview
 - 7.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings
 - 7.5.4 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2017-2022)
 - 7.5.5 Genentech, Inc. (U.S.) Key News

7.6 Cipla, Inc. (India)

7.6.1 Cipla, Inc. (India) Corporate Summary

7.6.2 Cipla, Inc. (India) Business Overview

7.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Major Product Offerings

7.6.4 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global Market (2017-2022)

7.6.5 Cipla, Inc. (India) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Opportunities & Trends in Global Market

Table 2. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Drivers in Global Market

Table 3. Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Restraints in Global Market

Table 4. Key Players of Human Immunodeficiency Virus (HIV)-1 Therapeutics in Global Market

Table 5. Top Human Immunodeficiency Virus (HIV)-1 Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Type

Table 9. List of Global Tier 1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Human Immunodeficiency Virus (HIV)-1 Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. AbbVie, Inc.(U.S.) Corporate Summary

Table 31. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings

Table 32. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. Merck & Co., Inc. (U.S.) Corporate Summary

Table 34. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings

Table 35. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Bristol-Myers Squibb Company (U.S.) Corporate Summary

Table 37. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings

Table 38. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Boehringer Ingelheim GmbH (Germany) Corporate Summary

Table 40. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings

Table 41. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Genentech, Inc. (U.S.) Corporate Summary

Table 43. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings

Table 44. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Cipla, Inc. (India) Corporate Summary

Table 46. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Offerings

Table 47. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Type in 2021

Figure 2. Human Immunodeficiency Virus (HIV)-1 Therapeutics Segment by Application in 2021

Figure 3. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue in 2021

Figure 8. By Type - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Human Immunodeficiency Virus (HIV)-1 Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/H681AA67BEF3EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H681AA67BEF3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

